142 related articles for article (PubMed ID: 1532323)
1. Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
Dundee JW; McMillan CM; Yang J; Wright PM
Br J Clin Pharmacol; 1992 Feb; 33(2):200-1. PubMed ID: 1532323
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
McMillan C; Dundee JW; Abram WP
Br J Cancer; 1991 Nov; 64(5):971-2. PubMed ID: 1834156
[No Abstract] [Full Text] [Related]
3. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
[TBL] [Abstract][Full Text] [Related]
4. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Egan AP; Taggart JR; Bender CM
Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
[TBL] [Abstract][Full Text] [Related]
5. Management of nausea and vomiting caused by anticancer drugs: state of the art.
Pisters KM; Kris MG
Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744
[TBL] [Abstract][Full Text] [Related]
6. Odansetron.
Betcher DL; Burnham N
J Pediatr Oncol Nurs; 1991 Oct; 8(4):183-5. PubMed ID: 1834086
[No Abstract] [Full Text] [Related]
7. [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
Sampi K; Taguchi T
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):922-8. PubMed ID: 2140498
[TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron, a new antiemetic therapy for oncology. An overview.
Lip H
Scand J Gastroenterol Suppl; 1990; 178():55-61. PubMed ID: 2148983
[TBL] [Abstract][Full Text] [Related]
10. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron: a new entity in emesis control.
Graves T
DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
[TBL] [Abstract][Full Text] [Related]
13. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Stewart DJ; Dahrouge S; Coyle D; Evans WK
J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
[TBL] [Abstract][Full Text] [Related]
15. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
17. Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
Kohler DR; Goldspiel BR
DICP; 1991 Apr; 25(4):367-80. PubMed ID: 1833888
[TBL] [Abstract][Full Text] [Related]
18. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
19. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
20. The role of ondansetron in paediatric patients: a review of three studies.
Stevens RF
Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
